x
ServiziMenu principaleHome
You are here: Home > Events > Past events > 2016 > ESNM-ESO Learning Course on 18FDG PET-CT in Lymphoma
Print

ESNM-ESO Learning Course on 18FDG PET-CT in Lymphoma

18.11.2016  -  19.11.2016

Vienna, Austria

ADVANCED COURSES & SEMINARS

Lymphoma

Description

Chairs: L. Ceriani, CH - S. Stroobants, BE


As a joint initiative, the European School of Nuclear Medicine and the European School of Oncology are pleased to announce the second edition of the ESNM/ESO course on 18FDG PET/CT in lymphoma.
There is a growing demand for academic education for oncologists/haematologists and nuclear physicians to increase their competence in interpreting PET-CT findings and using these data in the staging and treatment process. The recent publication of the consensus paper of the International Conference on Malignant Lymphomas - Imaging Working Group about the role of imaging together with the updated staging classification of malignant lymphomas (Lugano Classification, JCO 2014) confirmed the pivotal role of 18FDG PET-CT in the management of the lymphoproliferative diseases and the need to apply standard specific criteria to assure the best use of hybrid imaging not only in clinical studies but also  in everyday clinical practice.
The course is designed for oncologists/haematologists and nuclear physicians and aims at providing a clear knowledge of the meaning of the PET-CT findings in the different indolent and aggressive lymphoma types, the correct application of the Deauville criteria and their interpretation in staging and response assessment in patients with Hodgkin and non-Hodgkin lymphomas.



TARGET GROUP
The course is open to nuclear physicians, oncologists/haematologists and other specialists who seek training in the use of PET-CT imaging in the evaluation of patients with lymphomas, whether for daily practice or in a clinical research setting.
To guarantee high interactivity, attendance will be limited to 20 participants.


MAIN TOPICS
• Analysis of PET-CT data
• Image interpretation and description
• Classification
• Reporting and integration in the response assessment as well as practical sections covering
• Hodgkin lymphoma
• Diffuse large B-cell lymphoma
• Follicular lymphoma
• Primary mediastinal lymphoma


LEARNING OBJECTIVES
After the course the participants should:
• Improve interpretation skills in the evaluation of 18FDG PET-CT scans in patients with different types of lymphomas
• Learn how to implement the novel Lugano Classification for staging and response assessment
• Understand how to translate information into a nuclear medicine report that is clinically relevant
Learning objectives for each lecture are available HERE 

         
         
An initiative  held in cooperation with 
         
         
         

General information

ORGANISING SECRETARIAT
European School of Nuclear Medicine (ESNM)
Schmalzhofgasse 26
1060 Vienna, AUSTRIA
Tel: +43 (0) 1 890 44 27
Fax:
+43 (0) 1 890 44 27-9
eMail: a.falkner@eanm.org
eMail: esnm@eanm.org


VENUE
European School of Nuclear Medicine (ESNM)
Schmalzhofgasse 26
1060 Vienna

Austria

Faculty list


FACULTY

A. Biggi, Azienda Ospedaliera Sante Croce e Carle Cuneo, Cuneo, IT
L. Ceriani, Oncology Institute of Southern Switzerland, Bellinzona, CH
M. Meignan, Hôpitaux Universitaires Henri Mondor, Créteil, FR
S. Stroobants
, University Hospital Antwerp, Edegem, BE

J. Zijlstra, VU Medical Center, Amsterdam, NL
E. Zucca, Oncology Institute of Southern Switzerland, Bellinzona, CH

Programme

 

18 November

     
12:00   Welcome address and introduction of the instructors
Concept and goals of the course
12:15 - 13:00
Theoretical session 1
Malignant Lymphoma: classification and introduction
E. Zucca, CH
 14:30   Coffee break
13:15 - 14:15
Theoretical session 2
How to read and interpret PET-CT findings in lymphomas - The Lugano classification
M. Meignan, FR
14:15 - 15:00
Theoretical session 3
How to report PET-CT in lymphomas
L. Ceriani, CH
 15:00   Coffee break
15:30  -18:30
Theoretical session 4
Role of PET-CT in initial staging and treatment evaluation in lymphomas
15:30   Hodgkin lymphoma
A. Biggi, IT
16:15   DLBCL
S. Stroobants, BE
17:00   FollicularlLymphoma
J. Zijlstra, NL
17:45   PMBCL and mantle cell lymphoma
E. Zucca, CH
     

 

19 November

     
8:30   Presentation on handling of the workstations and how to read the studies
8:50   Form 4 groups of max. 5 people
9:00 - 14:30
Practical sessions 1-4 running in parallel
   
Practical session 1 Hodgkin lymphoma
A. Biggi, IT
    Practical session 2 PMBCL
L. Ceriani, CH
    Practical session 3 Follicular lymphoma
J. Zijlstra, NL
    Practical session 4 DLBCL
M. Meignan, FR
10:30   Coffee Break
12:15   Lunch Break
14:30   MCQs
 15:00   Coffee Break
15:15   Tumour board with discussion of the clinical cases reported by
the 4 groups
16:30   MCQs feedback and close
17:00   End of the course
     
     

 

 

 

Follow us